Alimera Appoints Maggie A. Pax to Its Board of Directors
November 08 2023 - 4:30PM
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global
pharmaceutical company whose mission is to be invaluable to
patients, physicians and partners concerned with retinal health and
maintaining better vision longer, today announces the addition of
Maggie A. Pax to its Board of Directors. Ms. Pax presently serves
on the board of several life sciences companies.
“Maggie’s experience within growing companies,
leading product development, business strategy, supply chain, and
commercial teams, along with leading the development of business
partnerships, will bring additional operational experience to our
board,” said Rick Eiswirth, Alimera’s President and Chief Executive
Officer. “Her leadership in companies ranging from early-stage
innovation to Fortune 500 size will provide us with new and unique
perspectives as we continue to scale.”
“Alimera is in an exciting stage of growth
following the acquisition of YUTIQ in the U.S. and continued
expansion in international markets,” added Ms. Pax. “I believe that
my history of strong operational leadership, product launch and
acquisition integration can provide further direction to this
leadership team.”
Ms. Pax is currently serving as a board member for
Jellagen Ltd., a privately-held company developing and
manufacturing tissue engineering and biomaterials products. She is
also on the board of BioPorto, Inc., a wholly-owned U.S. subsidiary
of a Denmark-listed in-vitro diagnostics innovator developing
biomarkers for kidney disease.
Ms. Pax was a senior executive at Thermo-Fisher
from 2012 to 2020 where her latest role was as Vice President,
Strategy and Innovation, Clinical Supply Chain / Pharma Services.
Previously, she served as Vice President, Business and Clinical
Development with Microchips BioMedical, a drug delivery company,
and Vice President, Business Development for CareScout, a
healthcare services company acquired by Genworth. Ms. Pax began her
career at Phillips Healthcare where she held senior leadership
roles in business development, marketing, and product management
from 1989 to 2000.
Ms. Pax holds an MBA from the Harvard Business
School and is a board director of the Harvard Business School
Healthcare Alumni Association.
About Alimera Sciences, Inc.
Alimera Sciences a global pharmaceutical company
whose mission is to be invaluable to patients, physicians and
partners concerned with retinal health and maintaining better
vision longer. For more information, please visit
www.alimerasciences.com.
Forward Looking Statements
This press release contains “forward-looking
statements,” within the meaning of the Private Securities
Litigation Reform Act of 1995, regarding, among other things,
Alimera’s expectations with respect to its growth and future
performance. Such forward-looking statements are based on
current expectations and involve inherent risks and
uncertainties (some of which are
beyond Alimera’s control), including factors that could
delay, divert or change any of them, and could cause actual results
to differ materially from those projected
in these forward-looking statements. Other factors are
discussed in the “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” sections
of Alimera’s recently filed Quarterly Report on Form 10-Q,
most recently filed Annual Report on Form 10-K, and any of
Alimera’s subsequent filings with the Securities and Exchange
Commission (SEC) and available on the SEC’s website
at www.sec.gov.
All forward-looking statements contained in this
press release are expressly qualified by the cautionary statements
contained or referred to herein. Alimera cautions investors not to
rely on the forward-looking statements Alimera makes or that are
made on its behalf as predictions of future events. These
forward-looking statements speak only as of the date of this press
release. Alimera undertakes no obligation, and specifically
declines any obligation, to publicly update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be required under
applicable securities laws.
For press inquiries:Jules Abrahamfor Alimera
Sciences917-885-7378julesa@coreir.com |
For investor inquiries:Scott Gordonfor Alimera
Sciencesscottg@coreir.com |
|
|
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/3459168c-4bc2-41b9-bf53-6bcdb320fd45
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Apr 2024 to May 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From May 2023 to May 2024